Tongeji E Tungaraza1, Saeed Farooq2. 1. Choice Lifestyles LTD, Birmingham B17 8LL, UK. 2. Black Country NHS Foundation Trust and Staffordshire University, UK.
Abstract
OBJECTIVES: It has been repeatedly shown that clozapine is underutilized and there is delayed use of it in clinical practice. METHOD: An online survey was sent to 2771 consultant psychiatrists registered with the Royal College of Psychiatrists in the UK. A total of 243 responded to this survey. The survey elicited their views and experiences in using clozapine as well as to identify what may be the underlying causes for its underutilization. RESULTS: Over 75% acknowledged that they had good training in using clozapine and about 56% had clozapine-dedicated service. However, 40.5% preferred to use several other antipsychotics prior to considering clozapine. A third felt it was not safe to start clozapine in the community and 42% had less than five patients on clozapine. Eleven possible reasons for clozapine underutilization were identified including concerns about side effects, patients not wanting to have blood tests and lack of experience or knowledge. Knowledge deficiency in certain aspects of clozapine use were identified, e.g. a third of respondents did not know that the risk of agranulocytosis changes with time, 42.7% did not think that clozapine can reduce substance use, while 20% were not aware of its benefit in reducing suicidal risk. CONCLUSIONS: Important areas of concern such as managing side effects and deficiency in evidence-based use of clozapine were identified. These can be targeted in training and professional development programme.
OBJECTIVES: It has been repeatedly shown that clozapine is underutilized and there is delayed use of it in clinical practice. METHOD: An online survey was sent to 2771 consultant psychiatrists registered with the Royal College of Psychiatrists in the UK. A total of 243 responded to this survey. The survey elicited their views and experiences in using clozapine as well as to identify what may be the underlying causes for its underutilization. RESULTS: Over 75% acknowledged that they had good training in using clozapine and about 56% had clozapine-dedicated service. However, 40.5% preferred to use several other antipsychotics prior to considering clozapine. A third felt it was not safe to start clozapine in the community and 42% had less than five patients on clozapine. Eleven possible reasons for clozapine underutilization were identified including concerns about side effects, patients not wanting to have blood tests and lack of experience or knowledge. Knowledge deficiency in certain aspects of clozapine use were identified, e.g. a third of respondents did not know that the risk of agranulocytosis changes with time, 42.7% did not think that clozapine can reduce substance use, while 20% were not aware of its benefit in reducing suicidal risk. CONCLUSIONS: Important areas of concern such as managing side effects and deficiency in evidence-based use of clozapine were identified. These can be targeted in training and professional development programme.
Authors: Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio Journal: Ther Adv Drug Saf Date: 2018-02-06
Authors: Kathleen Patchan; Gopal Vyas; Ann L Hackman; Marie Mackowick; Charles M Richardson; Raymond C Love; Ikwunga Wonodi; MacKenzie A Sayer; Matthew Glassman; Stephanie Feldman; Deanna L Kelly Journal: Psychiatr Q Date: 2018-03
Authors: Robert O Cotes; A Umair Janjua; Beth Broussard; David Lazris; Ayesha Khan; Yunshen Jiao; Sarah L Kopelovich; David R Goldsmith Journal: Community Ment Health J Date: 2021-05-29
Authors: Fahad D Alosaimi; Abdulhadi Alhabbad; Mohammed F Abalhassan; Ebtihaj O Fallata; Nasser M Alzain; Mohammad Zayed Alassiry; Bander Abdullah Haddad Journal: Neuropsychiatr Dis Treat Date: 2016-04-19 Impact factor: 2.570
Authors: Y C van der Zalm; P F Schulte; J P A M Bogers; F Termorshuizen; M Marcelis; M A G B van Piere; I E Sommer; J P Selten Journal: Adm Policy Ment Health Date: 2020-07
Authors: Imogen Stokes; Siân Lowri Griffiths; Rowena Jones; Linda Everard; Peter B Jones; David Fowler; Joanne Hodgekins; Tim Amos; Nick Freemantle; Vimal Sharma; Max Marshall; Swaran P Singh; Max Birchwood; Rachel Upthegrove Journal: BJPsych Open Date: 2020-09-17